| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,174 |
13.35 (1.15%) |
Mid Cap | 33,700 | 38.6 | 11.44 | 30.4 | 2.6 | |
| Cipla | Pharmaceuticals& Drugs | 1,450 |
0 (0%) |
Mid Cap | 28,163 | 41.7 | 13.45 | 34.8 | 3.3 | |
| Lupin | Pharmaceuticals& Drugs | 2,386 |
10 (0.42%) |
Mid Cap | 27,958 | 116.6 | 18.82 | 20.5 | 4.9 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,111 |
-7.5 (-0.67%) |
Mid Cap | 27,148 | 50.5 | 16.54 | 22 | 4.3 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,248 |
29 (1.31%) |
Mid Cap | 13,322 | 63.7 | 9.67 | 35.3 | 5.8 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,613.4 |
29.6 (1.87%) |
Mid Cap | 11,172 | 42 | 20.59 | 38.4 | 4.1 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,452 |
-9 (-0.37%) |
Mid Cap | 10,421 | 52.8 | 19.97 | 46.4 | 6 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,662.8 |
162.75 (2.96%) |
Mid Cap | 9,664 | 182.8 | 22.7 | 31 | 4.8 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,766.9 |
84.6 (5.03%) |
Mid Cap | 7,289 | 44.6 | 16.38 | 39.6 | 5.6 | |
| Abbott India | Pharmaceuticals& Drugs | 27,733.4 |
-112.45 (-0.4%) |
Mid Cap | 6,929 | 730.4 | 22.25 | 38 | 12.4 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,842.7 |
7.2 (0.39%) |
Mid Cap | 6,813 | 20.2 | 12.82 | 91.1 | 17.7 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,438.5 |
-83.85 (-2.38%) |
Mid Cap | 5,453 | 90.8 | 19.33 | 37.9 | 8.8 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,566.6 |
-80.9 (-3.06%) |
Mid Cap | 3,822 | 63.1 | 25.36 | 40.7 | 17.3 | |
| Biocon | Pharmaceuticals& Drugs | 425 |
-0.15 (-0.04%) |
Mid Cap | 2,346 | 0.6 | 5.85 | 708.9 | 2.5 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 825.8 |
7.15 (0.87%) |
Mid Cap | 2,089 | 11.1 | 30.95 | 74.5 | 14.3 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: